Sorghum Bicolor Whole

Dosage for Sorghum Bicolor Whole is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels and clinical history.

Diagnostic Dosing (Skin Testing)

• Skin Prick Test (SPT): One drop of the concentrated extract (e.g., 1:20 w/v) is applied to the skin, followed by a prick through the drop. Results are read at 15–20 minutes.
• Intradermal Test: If the SPT is negative, 0.02 mL of a 1:1000 or 1:500 dilution may be injected intradermally to confirm results.

Therapeutic Dosing (Immunotherapy)

• Build-up Phase: Typically starts at a very low dose (e.g., 0.05 mL of a 1:100,000 dilution) once or twice weekly. The dose is gradually increased until the maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose is achieved (the maintenance dose), injections are given less frequently, usually every 2 to 4 weeks.

Sorghum Bicolor Whole may be used in children, though the decision to start immunotherapy in very young children (typically under age 5) requires careful consideration of the child's ability to cooperate and the risks of systemic reactions. Dosage follows the same titration principles as adult dosing but may be adjusted based on the child's weight and sensitivity profile.

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the extract is not cleared through primary renal filtration. However, the patient's overall health must be stable before administration.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of being unable to tolerate the physiological stress of a systemic reaction or the administration of epinephrine must be weighed against the benefits of testing or therapy.

This product is never for self-administration. It must be administered in a clinical setting by a healthcare professional.

• Observation Period: Patients must remain in the clinic for at least 30 minutes following any injection or skin test to monitor for signs of anaphylaxis.
• Injection Site: Immunotherapy is given as a subcutaneous injection, typically in the posterior aspect of the upper arm.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

In the context of immunotherapy:

• If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay.
• If a dose is missed during the maintenance phase by more than 1–2 weeks, the allergist will typically reduce the dose to ensure safety before building back up.

An overdose of allergenic extract usually manifests as an immediate, severe systemic allergic reaction. Signs include:

• Generalized hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid drop in blood pressure (hypotension)
• Loss of consciousness

Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly is the primary treatment. Supportive care including oxygen, IV fluids, and antihistamines may follow.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Sorghum Bicolor Whole will experience some form of localized reaction. These are generally not dangerous but indicate the immune system is responding to the allergen.

• Local Redness (Erythema): Redness at the site of the skin test or injection.
• Swelling (Wheal): A raised, itchy bump at the injection site. This may appear immediately or several hours later (Late Phase Reaction).
• Pruritus (Itching): Intense itching at the site of administration.
• Tenderness: The area may feel sore or warm to the touch for 24–48 hours.

• Large Local Reactions: Swelling that exceeds 5–10 cm in diameter at the injection site.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy session.
• Mild Nasal Congestion: Occasional "hay fever" symptoms following an injection.

• Systemic Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Deep tissue swelling, often around the eyes or lips.
• Persistent Cough: A dry, hacking cough indicating mild bronchial irritation.

> Warning: Stop taking Sorghum Bicolor Whole and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Wheezing or Shortness of Breath: Indicates airway constriction (bronchospasm).
• Throat Tightness: Feeling as though the throat is closing or difficulty swallowing.
• Rapid Pulse or Dizziness: Signs of cardiovascular compromise or a drop in blood pressure.
• Nausea and Vomiting: Systemic involvement of the gastrointestinal tract during an allergic reaction.
• Cyanosis: Bluish tint to the skin or lips due to lack of oxygen.

There are no known long-term adverse effects associated with the proper use of Sorghum Bicolor Whole. In fact, the long-term goal of immunotherapy is a permanent reduction in allergic sensitivity. However, repeated large local reactions may occasionally lead to minor subcutaneous scarring (fibrosis) at the injection site over many years.

While Sorghum Bicolor Whole may not have a specific individual black box warning for every manufacturer, the class of Allergenic Extracts carries a general mandate for the following safety information:

• Risk of Anaphylaxis: Allergenic extracts can cause severe, life-threatening systemic reactions, including anaphylaxis and death.
• Supervision: Must be administered in a facility equipped to treat anaphylaxis.
• Observation: Patients must be observed for at least 30 minutes post-injection.
• Pre-existing Conditions: Patients with unstable asthma or those on beta-blockers are at increased risk of severe outcomes.

Report any unusual symptoms to your healthcare provider.

Sorghum Bicolor Whole is a potent biological substance. Its use is restricted to diagnostic and therapeutic protocols supervised by specialists. Patients must be informed that while the extract is intended to improve allergies, it carries an inherent risk of triggering the very symptoms it seeks to treat.

No specific FDA black box warning exists uniquely for Sorghum Bicolor Whole, but it falls under the general safety requirements for all non-standardized allergenic extracts. The primary warning emphasizes that these products can cause severe systemic reactions (anaphylaxis) and should only be used by physicians experienced in managing such emergencies.

• Anaphylaxis Risk: This is the most significant risk. Patients should be evaluated for their current health status before every injection. If a patient is experiencing an asthma flare or a high fever, the injection should be postponed.
• Asthma Status: Patients with severe or unstable asthma are at a much higher risk for fatal systemic reactions. Asthma must be well-controlled before starting immunotherapy.
• Epinephrine Availability: Patients on immunotherapy should be prescribed and trained to use an epinephrine auto-injector for potential delayed reactions that occur after leaving the clinic.
• Injection Technique: Accidental intravenous injection can cause immediate, severe anaphylaxis. The healthcare provider must always aspirate the syringe before injecting to ensure the needle is in the subcutaneous tissue.

• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after injections to ensure no significant drop in lung function.
• Vital Signs: Blood pressure and heart rate may be monitored if a systemic reaction is suspected.
• Injection Site Inspection: The site of the previous injection is checked for large local reactions before the next dose is given.

Generally, Sorghum Bicolor Whole does not affect the ability to drive. However, if a patient experiences dizziness or receives antihistamines/epinephrine for a reaction, they should not operate machinery until fully recovered.

Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption from the injection site and potentially increase the risk of a systemic reaction.

Immunotherapy is typically continued for 3 to 5 years. Stopping abruptly does not cause withdrawal symptoms, but the patient may experience a return of their original allergy symptoms if the desensitization process was not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Sorghum Bicolor Whole.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated in patients receiving allergenic extracts. Beta-blockers can make an allergic reaction more severe and, more critically, they interfere with the action of epinephrine, making it difficult to treat anaphylaxis if it occurs.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions during immunotherapy or skin testing.
• MAOIs (Monoamine Oxidase Inhibitors): These can potentiate the effects of sympathomimetics used to treat reactions, leading to hypertensive crises.

• Antihistamines (e.g., Loratadine, Cetirizine): While not dangerous, antihistamines will suppress the skin's response to the extract, leading to false-negative results in skin testing. Patients must stop antihistamines for 3–7 days before diagnostic testing.
• Tricyclic Antidepressants (TCAs): Similar to antihistamines, TCAs have potent H1-receptor blocking properties and can interfere with skin test results.

There are no direct chemical interactions between Sorghum Bicolor Whole and specific foods. However, if a patient has a known food allergy to sorghum, they should avoid consuming it during the initial phases of immunotherapy to prevent "stacking" the allergic load on the immune system.

• St. John’s Wort: May theoretically affect the metabolism of medications used to treat allergic reactions, though clinical evidence is limited.
• High-dose Vitamin C: Some evidence suggests it may have mild antihistamine properties which could subtly affect skin test sensitivity.

Sorghum Bicolor Whole does not interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Allergy Skin Tests: As intended, it produces a wheal and flare.
• Serum IgE Tests: Immunotherapy may lead to an initial rise in specific IgE followed by a long-term decrease, and an increase in specific IgG4 levels.

For each major interaction, the primary concern is either the masking of diagnostic results or the inability to treat an emergency reaction. Management usually involves temporary discontinuation of interfering drugs or choosing alternative diagnostic methods like in-vitro (blood) IgE testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Sorghum Bicolor Whole must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values or those with frequent exacerbations are at an unacceptably high risk of fatal anaphylaxis.
• Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The heart may not be able to tolerate the stress of a systemic reaction or the epinephrine required to treat it.
• Hypersensitivity to Diluents: If a patient is known to be allergic to phenol (a preservative) or glycerin (a stabilizer) used in the extract.
• Acute Infection: Injections should not be given during an active febrile illness.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical risk that immunotherapy could exacerbate certain autoimmune conditions.
• Malignancy: Patients with active cancer may have altered immune responses.
• Severe Atopic Dermatitis: May make the interpretation of skin tests difficult.

Patients sensitive to Sorghum Bicolor Whole may also show cross-reactivity with other members of the Poaceae family, particularly Johnson Grass (Sorghum halepense), Corn (Zea mays), and Sugarcane (Saccharum officinarum). This is due to the presence of conserved pan-allergens (proteins that are similar across different species).

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Sorghum Bicolor Whole.

• FDA Pregnancy Category: Not formally assigned, but generally considered Category C.
• Risks: The primary risk during pregnancy is not the extract itself, but the risk of maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen).
• Clinical Guidance: It is generally recommended not to start new immunotherapy during pregnancy. However, if a patient is already on a maintenance dose and tolerating it well, the allergist may choose to continue the therapy at the same or a slightly reduced dose.

Sorghum Bicolor Whole is not known to pass into breast milk in any significant quantity. It is generally considered safe for nursing mothers to continue immunotherapy. There are no known adverse effects on the nursing infant.

• Approved Age: There is no strict lower age limit, but most clinicians wait until a child is at least 5 years old.
• Considerations: Children must be able to communicate symptoms of a systemic reaction. Growth and development are not affected by allergenic extracts.

In patients over 65, the decision to use Sorghum Bicolor Whole must consider the higher prevalence of cardiovascular disease and the use of medications like beta-blockers. The ability of the elderly patient's heart to withstand a systemic reaction is the primary safety concern.

No dosage adjustments are needed. The proteins in the extract are not cleared by the kidneys in a way that would lead to accumulation or toxicity in the setting of renal failure.

No dosage adjustments are needed. Liver function does not significantly impact the processing or safety of allergenic extracts.

> Important: Special populations require individualized medical assessment.

Sorghum Bicolor Whole works by presenting specific protein antigens to the immune system. In sensitized individuals, these proteins (such as Sor b 1, a major pollen allergen) bind to IgE on mast cells. For therapy, the repeated, escalating exposure induces Immune Tolerance. This involves:

1. 1T-cell Anergy: Reducing the responsiveness of allergen-specific T-cells.
2. 2Treg Induction: Increasing Regulatory T-cells that secrete IL-10 and TGF-beta.
3. 3B-cell Switching: Shifting B-cell production from IgE to IgG4, which acts as a 'decoy' or blocking antibody.

• Onset of Action: Skin test results are visible within 15–20 minutes. For immunotherapy, clinical improvement typically takes 6–12 months of consistent treatment.
• Duration of Effect: The effects of a successful 3–5 year course of immunotherapy can last for many years, or even a lifetime, after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | Primarily to IgE and IgG4 antibodies |

| Half-life | Proteins are degraded within hours/days at the site |

| Tmax | 15–30 minutes for IgE-mediated local reaction |

| Metabolism | Proteolysis by antigen-presenting cells |

| Excretion | Not renally excreted; catabolized into amino acids |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from Sorghum bicolor.
• Molecular Weight: Varies (typical allergens range from 10 kDa to 70 kDa).
• Solubility: Soluble in aqueous buffers and glycerin-saline solutions.

Sorghum Bicolor Whole is a Non-Standardized Allergenic Extract. It belongs to the broader class of biologicals used in in-vivo diagnostic and immunotherapeutic applications.